Overview

Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients

Status:
Not yet recruiting

Trial end date:
2025-08-01

Target enrollment:
0

Participant gender:
Female

Summary

Eligible patients will be divided into two groups; one will receive neoadjuvant endocrine therapy and the other one will receive neoadjuvant chemotherapy.

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Sohag University

Treatments:

Antineoplastic Agents
Antineoplastic Agents, Hormonal

Criteria

Inclusion Criteria:

- Any histological type of invasive breast cancer. All grades of breast cancer (I, II,
III). ER-positive and/or PR-positive, HER2-negative breast cancer. ER and/or PR level
of positivity ≥34 % (score 4 according to modified Allred score).

Clinical Stages: any T N1-3, or T2-4 any N, M0.

Exclusion Criteria:

- Hormone receptor positivity < 34%. inflammatory breast cancer Metastatic breast
cancer. Recurrent breast cancer. Other malignancy. Unfit patients for chemotherapy.